Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes?

Progress in Retinal and Eye Research

Volumn 30, Issue 2, 2011, Pages 129-146

  Jager, Martine J ^a,b   Ly, Long V ^a   El Filali, Mariam ^a   Madigan, Michele C ^c,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Immune privilege; Inflammation; Macrophage; Ocular oncology; Uveal melanoma; Vascular endothelial growth factor

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACENTAL GROWTH FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; CELL POPULATION; CORNEA CELL; EYE TUMOR; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCAVENGING SYSTEM; TUMOR GROWTH; UVEA MELANOMA; WOUND HEALING;

AGING; ANIMALS; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; MACROPHAGES; MATRIX METALLOPROTEINASES; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROGNOSIS; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551644530     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2010.11.004     Document Type: Review

References (177)

1. Abdel-Rahman M.H., Craig E.L., Davidorf F.H., Eng C. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin. Cancer Res. 2005, 11:73-78.
2. Allavena P., Sica A., Garlanda C., Mantovani A. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222:155-161.
3. Apte R.S., Richter J., Herndon J., Ferguson T.A. Macrophages inhibit neovascularisation in a murine model of age-related macular degeneration. PLoS Med. 2006, 3:e310-e320.
4. Ashcroft G.S., Horan M.A., Ferguson M.W.J. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J. Invest. Dermatol. 1997, 108:430-437.
5. Augsburger J.J., Correa Z.M., Shaikh A.H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 2009, 148:119-127.
6. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
7. Bergman L., Seregard S., Nilsson B., Ringborg U., Lundell G., Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest. Ophthalmol. Vis. Sci. 2002, 43:2579-2583.
8. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 1993, 11:767-804.
9. Blom D.J.-R., Luyten G.P., Mooy C., Kerkvliet S., Zwinderman A.H., Jager M.J. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 1997, 38:1865-1872.
10. Boonman Z.F.H.M., van Mierlo G.J.D., Fransen M.F., De Keizer R.J.W., Jager M.J., Melief C.J.M., Toes R.E.M. Maintenance of immune tolerance depends on normal tissue homeostasis. J. Immunol. 2005, 175:4247-4254.
11. Boonman Z.F.H.M., Schurmans L.R.H.M., van Rooijen N., Melief C.J.M., Toes R.E.M., Jager M.J. Macrophages are vital in spontaneous intraocular tumor eradication. Invest. Ophthalmol. Vis. Sci. 2006, 47:2959-2965.
12. Bosch J.J., Thompson J.A., Srivastava M.K., Iheagwara U.K., Murray T.G., Lotem M., Ksander B.R., Ostrand-Rosenberg S. MHC Class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 2007, 67:4499-4506.
13. Bosco M.C., Puppo M., Blengio F., Fraone T., Cappello P., Giovarelli M., Varesio L. Monocytes and dendritic cells in a hypoxic environment: spotlights on chemotaxis and migration. Immunobiology 2008, 213:733-749.
14. Bougatef F., Quemener C., Kellouche S., Naimi B., Podgorniak M.P., Millot G., Gabison E.E., Calvo F., Dosquet C., Lebbe C., Menashi S., Mourah S. EMMPRIN promotes angiogenesis through HIF-2alpha mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009, 114:5547-5556.
15. Boyd S.R., Tan D., Bruce C., Gittos A., Neale M.H., Hungerford J.L., Charnock-Jones S., Cree I.A. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br. J. Ophthalmol. 2002, 86:448-452.
16. Boyd S.R., Tan D.S., de Souza L., Neale M.H., Myatt N.E., Alexander R.A., Robb M., Hungerford J.L., Cree I.A. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br. J. Ophthalmol. 2002, 86:440-447.
17. Boyd S.R., Gittos A., Richter M., Hungerford J.L., Errington R.D., Cree I.A. Proton beam therapy and iris neovascularisation in uveal melanoma. Eye 2006, 20:832-836.
18. Boyle G.M., Pedley J., Martyn A.C., Banducci K.J., Strutton G.M., Brown D.A., Breit S.N., Parsons P.G. Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J. Invest. Dermatol. 2009, 129:383-391.
19. Bronkhorst I.H.G., Ly L.V., Jordanova E.S., Vrolijk H., Versluis M., Luyten G.P.M., Jager M.J. Detection of M2 macrophages in uveal melanoma and relation with survival. Invest. Ophthalmol. Vis. Sci 2010, doi:10.1167/iovs.10-5979.
20. COMS Development of metastatic disease after enrolment in the COMS trials for treatment of choroidal melanoma. Arch. Ophthalmol. 2005, 123:1639-1643.
21. Campochiaro P.A. Ocular versus extraocular neovascularisation: mirror images or vague resemblances. Invest. Ophthalmol. Vis. Sci. 2006, 47:462-474.
22. Carr I. The Macrophage. A Review of Ultrastructure and Function 1973, Academic Press, London.
23. Chang S.-H., Worley L.A., Onken M.O., Harbour J.W. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008, 18:191-200.
24. Chen P.W., Mellon J.K., Mayhew E., Wang S., He Y.G., Hogan N., Niederkorn J.Y. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp. Eye Res. 2007, 85:617-625.
25. Clarijs R., Schalkwijk L., Ruiter D.L., De Waal R.M. Lack of lamphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:1422-1428.
26. Clarijs R., Schalkwijk L., Ruiter D.J., de Waal R.M.W. EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:1801-1806.
27. Corrie P.G., Shaw J., Spanswick V.J., Sehmbi R., Jonson A., Mayer A., Bulusu R., Hartley J.A., Cree I.A. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br. J. Cancer 2005, 92:1997-2003.
28. Coupland S.E., Campbell I., Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology 2008, 115:1778-1785.
29. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 2004, 113:1040-1050.
30. Dace D.S., Khan A.A., Kelly J., Apte R.S. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS ONE 2008, 3(10):e3381.
31. Dace D.S., Chen P.W., Niederkorn J.Y. CD4+ T cell-dependent tumor rejection in an immune-privileged environment requires macrophages. Immunology 2008, 123:367-377.
32. Davidorf F.H., Lang J.R. Immunology and immunotherapy of malignant uveal melanomas. Intraocular Tumors 1977, 119-133. Appleton/Century/Crofts, New York. G.A. Peyman, D.J. Apple, D.R. Sanders (Eds.).
33. De Vries E., van der Weij J.P., van der Veen C.J.P., van Paassen H.C., Jager M.J., Sleeboom H.P., Bijvoet O.L.M., Cats A. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-biphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 1982, 47:157-163.
34. De Waard-Siebinga I., Hilders C.G.J.M., Hansen B.E., van Delft J.L., Jager M.J. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:34-42.
35. De la Cruz P.O., Specht C.S., McLean I.W. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990, 65:112-115.
36. Diez-Roux G., Lang R.A. Macrophages induce apoptosis in normal cells in vivo. Development 1997, 124:3633-3638.
37. Ding X., Patel M., Chan C.-C. Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 2009, 28:1-18.
38. Dissanayake S.K., Thompson J.A., Bosch J.A., Clements V.K., Chen P.W., Ksander B.R., Ostrand-Rosenberg S. Activation of tumor-specific CD4+ T lymphocytes by major histocompatibility class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 2004, 64:1867-1874.
39. Dithmar S., Crowder J., Jager M.J., Vigniswaran N., Grossniklau H.E. HLA-I-Antigenexpression korreliert mit dem histologischen Zelltyp Uvealer Melanome. Ophthalmologe 2002, 99:625-628.
40. Dolcetti L., Marigo I., Mantelli B., Peranzoni E., Zanovello P., Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 2008, 267:216-225.
41. Dror R., Lederman M., Umezawa K., Barak V., Pe'er J., Chowers I. Characterizing the involvement of the nuclear factor/kappa B (NFkB) transcription Factor in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2010, 51:1811-1816.
42. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., Asosingh K., Erzurum S., Anand-Apte B. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularisation in vivo. Am. J. Pathol. 2010, 176:496-503.
43. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
44. El Filali M., Homminga I., Maat W., Van der Velden P.A., Jager M.J. Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. Mol. Vis. 2008, 14:1752-1759.
45. El Filali M., Missotten G.S., Maat W., Ly L.V., Luyten G.P., Van der Velden P.A., Jager M.J. Regulation of VEGF-A in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2010, 51:2329-2337.
46. El-Shabrawi Y., Ardjomand N., Radner H., Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J. Pathol. 2001, 194:201-206.
47. Ericsson C., Seregard S., Bartolazzi A., Levitskaya E., Ferrone E., Kiessling R., Larsson O. Association of HLA class I and II antigen expression and mortality in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:2153-2156.
48. Espinosa-Heidmann D.G., Suner I., Hernandez E.P., Frazier W.D., Csaky K.G., Cousins S.W. Age as an independent risk factor for severity of experimental choroidal neovascularisation. Invest. Ophthalmol. Vis. Sci. 2002, 43:1567-1573.
49. Espinosa-Heidmann D.G., Suner I.J., Hernandez E.P., Monroy D., Csaky K.G., Cousins S.W. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularisation. Invest. Ophthalmol. Vis. Sci. 2003, 44:3586-3592.
50. Eter N., Engel D.R., Meyer L., Helb H.-M., Roth F., Maurer J., Holz F.G., Kurts C. In vivo visualization of dendritic cells, macrophages, and microglial cells responding to laser-induced damage in the fundus of the eye. Invest. Ophthalmol. Vis. Sci. 2008, 49:3649-3658.
51. Figueiredo A., Caissie A.L., Callejo S.A., McLean I.W., Gold P., Burnier M.N. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can. J. Ophthalmol. 2003, 38:352-356.
52. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 2000, 156:361-381.
53. Foss A.J., Alexander R.A., Jefferies L.W., Hungerford J.L., Harris A.L., Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996, 56:2900-2903.
54. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat. Rev. Immunol. 2004, 4:941-952.
55. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
56. Gazzaniga S., Bravo A.I., Guglielmotti A., van Rooijen N., Maschi F., Vecchi A., Montovani A., Mordoh J., Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 2007, 127:2031-2041.
57. Gragoudas E.S., Egan K.M., Seddon J.M., Glynn R.J., Welsh S.M., Finn S.M., Munzenrider J.E., Spar M.D. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991, 98:383-389.
58. Hallermalm K., Seki K., De Geer A., Motyka B., Bleackley R.C., Jager M.J., Frohlich C.J., Levitsky V., Levitskaya J. Modulation of the tumor cell phenotype by IFN gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J. Immunol. 2008, 180:3766-3774.
59. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
60. Hendrix M.J., Seftor E.A., Seftor R.E., Gardner L.M., Boldt H.G., Meyer M., Pe'er J., Folberg R. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers. Lab. Invest. 1998, 78:153-163.
61. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
62. Hofmann U.B., Westphal J.R., van Kraats A.A., Ruiter D.J., Van Muijen G.N. Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int. J. Cancer 2000, 87:12-19.
63. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1:149-153.
64. Hu J., Wang Y., Xie L. Potential role of macrophages in experimental keratomycosis. Invest. Ophthalmol. Vis. Sci. 2009, 50:2087-2094.
65. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD15+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
66. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., Feng Z.H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252:86-92.
67. IJland S.A., Jager M.J., Heijdra B.M., Westphal J.R., Peek R. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999, 9:445-450.
68. Iida J., McCarthy J.B. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res. 2007, 17:205-213.
69. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Ogushi Y., Ambati J., Miller J.W., Gragoudas E.S., Ng Y.-S., D'Amore P.A., Shima D.T., Adamis A.A. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularisation. J. Exp. Med. 2003, 198:483-489.
70. Itaya M., Sakurai E., Nozaki M., Yamada K., Yamasaki S., Asai K., Ogura Y. Upregulation of VEGF in murine retina via monocyte recruitment after retinal scatter laser photocoagulation. Invest. Ophthalmol. Vis. Sci. 2007, 48:5677-5683.
71. Jager M.J. Angiogenesis in uveal melanoma. Ophthalmic Res. 2006, 38:248-250.
72. Jager M.J., Klaver C.C.W. Macrophages feel their age in macular degeneration. J. Clin. Invest. 2007, 117:3182-3184.
73. Jager M.J., Claas F.H.J., Witvliet M., van Rood J.J. Correspondence of the monocyte antigen HMA-1 to the non-HLA antigen 9a. Immunogenetics 1986, 23:71-77.
74. Jager M.J., Claas F.H.J., D'Amaro J., Baldwin W.M., van Rood J.J. Two alloantigens on human monocytes: a diallelic system?. Hum. Immunol. 1987, 19:215-224.
75. Jager M.J., Hurks H.M., Levitskaya J., Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum. Immunol. 2002, 63:444-451.
76. Johansson C.C., Mougiakakos D., Trocme E., All-Ericsson C., Economou M.A., Larsson O., Seregard S., Kiessling R. Expression and prognostic significance of iNOS in uveal melanoma. Int. J. Cancer 2010, 126:2682-2689.
77. Kelly J., Khan A.A., Yin J., Ferguson Th.A., Apte R.S. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J. Clin. Invest. 2007, 117:3421-3426.
78. Kerr E.C., Raveney B.J., Copland D.A., Dick A.D., Nicholson L.B. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 2008, 31:354-361.
79. Kim S., Takahashi H., Lin W.-W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
80. Knisely T.L., Luckenbach M.W., Fischer B.J., Niederkorn J.Y. Destructive and non-destructive patterns of immune rejection of syngeneic intraocular tumors. J. Immunol. 1987, 138:4515-4523.
81. Kodjikian L., Grange J.D., Baldo S., Baillif S., Garweg J.G., Rivoire M. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:985-993.
82. Kodukula P., Liu T., van Rooijen N., Jager M.J., Hendricks R.L. Macrophage control of Herpes Simplex virus type 1 replication in the peripheral nervous system. J. Immunol. 1999, 162:2895-2905.
83. Kujala E., Mäkitie T., Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:4651-4659.
84. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003, 63:4441-4449.
85. Kvanta A., Steen B., Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp. Eye Res. 1996, 63:511-518.
86. Lai K., Conway R.M., Crouch R., Jager M.J., Madigan M.C. Expression and distribution of MMP's and TIMP's in human uveal melanoma. Exp. Eye Res. 2008, 86:936-941.
87. Lane A.M., Egan K.M., Yang J., Saornil M.A., Alroy J., Albert D., Gragoudas E.S. An evaluation of tumor vascularity as a prognostic indicator in uveal melanoma. Melanoma Res. 1997, 7:237-242.
88. Lang R.A., Bishop M.J. Macrophages are required for cell death and tissue remodelling in the developing mouse eye. Cell 1993, 74:453-462.
89. Lau S.K., Chu P.G., Weiss L.M. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am. J. Clin. Pathol. 2004, 122:794-801.
90. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
91. Li H., Alizadeh H., Niederkorn J.Y. Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest. Ophthalmol. Vis. Sci. 2008, 49:636-643.
92. Li H., Yang W., Chen P.W., Alizadeh H., Niederkorn J.Y. Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Invest. Ophthalmol. Vis. Sci. 2009, 50:5522-5528.
93. Lolmede K., Campana L., Vezzoli M., Bosurgi L., Tonlorenzi R., Clementi E., Bianchi M.E., Cossu G., Manfredi A.A., Brunelli S., Rovere-Querini P. Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J. Leukoc. Biol. 2009, 85:779-787.
94. Lutzky J., Weber R., Nunez Y., Gillett M., Spitler L. A phase 1 study of granulocyte macrophage colony-stimulating factor (Sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. J. Immunother. 2009, 32:79-85.
95. Ly L.V., Odish O.F., de Wolff-Rouendaal D., Missotten G.S., Luyten G.P., Jager M.J. Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey. Invest. Ophthalmol. Vis. Sci. 2010, 51:658-665.
96. Ly L.V., Baghat A., Versluis M., Jordanova E.S., Luyten G.P.M., van Rooijen N., van Hall T., van der Velden P.A., Jager M.J. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J. Immunol. 2010, 185:3481-3488.
97. Ly L.V., Sluijter M., Versluis M., Luyten G.P.M., van der Burg S.H., Melief C.J.M., Jager M.J., van Hall T. Peptide vaccination after T cell transfer causes massive clonal expansion, tumor eradication and manageable cytokine storm. Cancer Res. 2010, 70:8339-8346.
98. Ly L.V., Bronkhorst I.H.G., Beelen E., van, Vrolijk J., Taylor A.W., Versluis M., Luyten G.P., Jager M.J. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest. Ophthalmol. Vis. Sci. 2010, 51:5445-5451. doi:10.1167/iovs.10-5526.
99. Maat W., Ly L.V., Jordanova E.S., de Wolff-Rouendaal D., Schalij-Delfos N.E., Jager M.J. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2008, 49:505-510.
100. Maat W., El Filali M., Dirks-Mulder A., Luyten G.P., Gruis N.A., Desjardins L., Boender P., Jager M.J., van der Velden P.A. Episodic Src activation in uveal melanoma revealed by kinase activity profiling. Br. J. Cancer 2009, 101:312-319.
101. Mäkitie T., Summanen P., Tarkkanen A., Kivelä T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest. Ophthalmol. Vis. Sci. 1999, 40:2471-2480.
102. Mäkitie T., Summanen P., Tarkkanen A., Kivelä T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:1414-1421.
103. Mäkitie T., Carpen O., Vaheri A., Kivelä T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:2442-2449.
104. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
105. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
106. Marigo I., Dolcetti L., Serafini P., Zonovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222:162-179.
107. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van Rooijen N., Takenaka H., D'Amore P.A., Stein-Streilein J., Losordo D.W., Streilein J.W. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 2005, 115:2363-2372.
108. McClellan S.A., Huang X., Barrett R.P., van Rooijen N., Hazlett L.D. Macrophages restrict Pseudomonas aeruginosa growth, regulate polymorphonuclear neutrophil influx, and balance pro- and anti-inflammatory cytokines in BALB/c mice. J. Immunol. 2003, 170:5219-5227.
109. McKenna K.C., Kapp J.A. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J. Immunol. 2006, 177:1599-1608.
110. McKenna K.C., Beatty K.M., Bilonick R.A., Schoenfield L., Lathrop K.L., Singh A.D. Activated CD11b+ CD15+ granulocytes increase in blood of uveal melanoma patients. Invest. Ophthalmol. Vis. Sci. 2009, 50:4295-4303.
111. McLean I.W., Foster W.D., Zimmerman L.E. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum. Pathol. 1982, 13:123-132.
112. McMenamin P.G. Dendritic cells and macrophages in the uveal tract of the normal mouse eye. Br. J. Ophthalmol. 1999, 83:598-604.
113. Missotten G.S.O.A., Notting I.C., Schlingemann R.O., Zijlmans H.J., Lau C., Eilers P.H., Keunen J.E., Jager M.J. Vascular endothelial growth factor-A in eyes with uveal melanoma. Arch. Ophthalmol. 2006, 124:1428-1434.
114. Miyamoto K., Khosrof S., Bursell S.-E., Moromizato Y., Aiello L.P., Ogura Y., Adamis A.P. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by Intercellular Adhesion Molecule-1 (ICAM-1). Am. J. Pathol. 2000, 156:1733-1739.
115. Moldovan N.I. Role of monocytes and macrophages in adult angiogenesis: a light at the tunnel's end. J. Hematother. Stem Cell Res. 2002, 11:179-194.
116. Mooy C.M., De Jong P.T. Prognostic parameters in uveal melanoma: a review. Surv. Ophthalmol. 1996, 41:215-228.
117. Mougiakakos D., Johansson C.C., Trocme E., All-Ericsson C., Economou M.A., Larsson O., Seregard S., Kiessling R. Intratumoral Forkhead Box P3-positive regulatory t cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 2010, 116:2224-2233.
118. Mudhar H.S., Parsons M.A., Sisley K., Rundle P., Singh A., Rennie I.G. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004, 45:1-12.
119. Neale M.H., Myatt N.E., Khoury G.G., Weaver P., Lamont A., Hungerford J.L., Kurbacher C.M., Hall P., Corrie P.G., Cree I.A. Comparison of ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res. 2001, 11:601-609.
120. Nguyen T.T., Schwartz E.J., West R.B., Warnke R.A., Arber D.A., Natkunam Y. Expression of CD163 (haemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted tot the monocyte/macrophage lineage. Am. J. Surg. Pathol. 2005, 29:617-624.
121. Niederkorn J.Y. Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res. 2009, 28:329-347.
122. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004, 64:7205-7209.
123. Onken M.D., Lin A.Y., Worley L.A., Folberg R., Harbour J.W. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am. J. Ophthalmol. 2005, 140:748-749.
124. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
125. Overall C.M., Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 2006, 94:941-946.
126. Pe'er J., Shweiki D., Itin A., Hemo I., Gnessin H., Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 1995, 72:638-645.
127. Penfold P.L., Madigan M.C., Gillies M.C., Provis J.M. Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye Res. 2001, 20:385-414.
128. Polak M.E., Borthwick N.J., Jager M.J., Cree I.A. Dendritic cell-mediated immunosuppression in malignant melanoma. Cancer Ther. 2003, 1:393-405.
129. Polak M., Borthwick N.J., Johnson P., Hungerford J.L., Higgins B., Di Palma S., Jager M.J., Cree I.A. Presence and phenotype of dendritic cells in uveal melanoma. Br. J. Ophthalmol. 2007, 91:971-976.
130. Pollard J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9:259-270.
131. Radnot M., Antal M. Vessels of intraocular malignant melanomas. Am. J. Ophthalmol. 1979, 88:472-478.
132. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodelling and vascular disease. Biochem. Pharmacol. 2007, 75:346-359.
133. Repp A.C., Mayhew E.S., Apte S., Niederkorn J.Y. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J. Immunol. 2000, 165:710-715.
134. Sahin A., Kiratli H., Soylemezoglu F., Tezel G.G., Bilgic S., Saracbasi O. Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas. Jpn. J. Ophthalmol. 2007, 51:325-331.
135. Saio M., Radoja S., Marino M., Frey A.B. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 2001, 167:5583-5593.
136. Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularisation. Invest. Ophthalmol. Vis. Sci. 2003, 44:3578-3585.
137. Schaling, D.F., 1996. Radionuclides and radiolabelled antibodies in choroidal melanoma. Thesis, Leiden University.
138. Schurmans L.R.H.M., Blom D.J.R., De Waard-Siebinga I., Keunen J.E.E., Prause J.U., Jager M.J. Effects of transpupillary thermotherapy on immunological parameters and apoptosis in a case of primary uveal melanoma. Melanoma Res. 1999, 9:297-302.
139. Schurmans L.R., Diehl L., den Boer A.T., Sutmuller R.P., Boonman Z.F., Medema J.P., van der Voort E.I., Laman J., Melief C.J., Jager M.J., Toes R.E. Rejection of intraocular tumors by CD4+ T cells without induction of phthisis. J. Immunol. 2001, 167:5832-5837.
140. Seddon J.M., Albert D.M., Lavin P.T., Robinson N. A prognostic factor study of disease-free interval and survival following enucleation of uveal melanoma. Arch. Ophthalmol. 1983, 101:1894-1899.
141. Seftor R.E., Seftor E.A., Koshikawa N., Meltzer P.S., Gardner L.M., Bilban M., Stetler-Stevenson W.G., Quaranta V., Hendrix M.J. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001, 61:6322-6327.
142. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8(4 Suppl.):S62-S67.
143. Sheidow T.G., Hooper P.L., Crukley C., Young J., Heathcote J.G. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br. J. Ophthalmol. 2000, 84:750-756.
144. Sica A., Allavena P., Mantovani A. Cancer-related inflammation: the macrophage connection. Cancer Lett. 2008, 264:204-215.
145. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
146. Sikora A.G., Gelbard A., Davies M.A., Sano D., Ekmekcioglu S., Kwon J., Hailemichael Y., Jayaraman P., Myers J.N., Grimm E.A., Overwijk W.W. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin. Cancer Res. 2010, 16:1834-1844.
147. Singh A.D., Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003, 110:956-961.
148. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007, 179:977-983.
149. Slegers T.P.A., Broersma L., van Rooijen N., Hooymans J.M.M., van Rij G., van der Gaag R. Macrophages play a role in the early phase of corneal allograft rejection in rats. Transplantation 2004, 77:1641-1646.
150. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 10:415-433.
151. Stitt A.W., Simpson D.A., Boocock C., Gardiner T.A., Murphy G.M., Archer D.B. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumors. J. Pathol. 1998, 186:306-312.
152. Streilein J.W., Masli S., Takeuchi M., Kezuka T. The eye's view of antigen presentation. Hum. Immunol. 2002, 63:435-443.
153. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectivity eliminates splenic Gr1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances anti-tumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
154. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007, 26:373-400.
155. Tauber A.I. Metchnikoff and the phagocytosis theory. Nat. Rev. Mol. Cell Biol. 2003, 4:897-901.
156. Toivonen P., Mäkitie T., Kujala E., Kivelä T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest. Ophthalmol. Vis. Sci. 2004, 45:1-6.
157. Torisu H., Ono M., Kiryu H., Furue M., Ohmoto Y., Nakayama J., Nishioka Y., Sone S., Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalfa and IL-1a. Int. J. Cancer 2000, 85:182-188.
158. Väisänen A., Kallioinen M., von Dickhoff K., Laatikainen L., Höyhtyä M., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein- a new prognostic marker in uveal melanoma?. J. Pathol. 1999, 1888:56-62.
159. Van Furth R., Cohn Z.A., Hirsch J.G., Humphrey J.H., Spector W.G., Langevoort H.L. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull. World Health Organ 1972, 46:845-852.
160. Van Klink F., Taylor W.M., Alizadeh H., Jager M.J., van Rooijen N., Niederkorn J.Y. The role of macrophages in Acanthamoeba keratitis. Invest. Ophthalmol. Vis. Sci. 1996, 37:1271-1281.
161. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994, 174:83-93.
162. Van Rooijen N., Sanders A., van den Berg T.K. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J. Immunol. Methods 1996, 193:93-99.
163. Van der Schaft D.W., Seftor R.E., Seftor E.A., Hess A.R., Gruman L.M., Kirschmann D.A., Yokoyama Y., Griffioen A.W., Hendrix M.J. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J. Natl. Cancer Inst. 2004, 96:1473-1477.
164. Van der Velden P.A., Zuidervaart W., Hurks M.H., Pavey S., Ksander B.R., Krijgsman E., Frants R.R., Tensen C.P., Willemze R., Jager M.J., Gruis N.A. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer 2003, 106:472-479.
165. Venneri M.A., De Palma M., Ponzoni M., Pucci F., Scielzo C., Zonari E., Mazzieri R., Doglioni C., Naldini L. Identification of pro-angiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007, 109:5276-5285.
166. Vicetti Miguel R.D., Cherpes T.L., Watson L.J., McKenna K.C. CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination. J. Immunol. 2010, 185:6706-6718. 10.4049/jimmunol.0903411.
167. Victor N., Ivy A., Jiang B.-H., Agani F.H. Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin. Exp. Metastasis 2006, 23:87-96.
168. Vinores S.A., Kuchle M., Mahlow J., et al. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/permeability factor. Am. J. Pathol. 1995, 147:1289-1297.
169. Vit V.V. Prognostic role of morphological characteristics of the immune response in uveal melanoblastomas of various types. Arkh. Patol. 1983, 45:25-30.
170. Wang S., Boonman Z.F.H.M., Li H.-C., He Y.-G., Jager M.J., Toes R.E.M., Niederkorn J.Y. Role of TRAIL and IFN gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J. Immunol. 2003, 171:2789-2796.
171. Westphal J.R., Van't Hullenaar R., Peek R., Willems R.W., Crickard K., Crickard U., Aska J., Clemmensen I., Ruiter D.J., De Waal R.M. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer 2000, 86:768-776.
172. Whelchel J.C., Farah S.E., McLean I.W., Burnier M.N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest. Ophthalmol. Vis. Sci. 1993, 34:2603-2606.
173. Woodward J., Sisley K., Reeves G., Nichols C., Parsons M.A., Mudhar H., Rennie I. Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluritotency by expressing CD68 and CD163. Int. J. Exp. Pathol. 2004, 85:35-43.
174. Xu H., Chen M., Forrester J.V. Para-inflammation in the aging retina. Prog. Retin. Eye Res. 2009, 28:348-368.
175. Yang H., Jager M.J., Grossniklaus H.E. Bevacizumab suppresses establishment of micrometastases of experimental ocular melanoma. Invest. Ophthalmol. Vis. Sci. 2010, 51:2835-2842.
176. Young M.R., Halpin J., Hussain R., Lozano Y., Djordjevic A., Devata S., Matthews J.P., Wright M.A. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion Metastasis 1993, 13:169-177.
177. Zhu M., Madigan M.C., Van Driel D., Maslim J., Billson F.A., Provis J.M., Penfold P.L. The human hyaloid system: cell death and vascular regression. Exp. Eye Res. 2000, 70:767-776.